Primary outcome(s): Correlation between PD-L1 expression in immune cells and soluble PD-L1 value. Correlation between PD-L1 expression in immune cells or soluble PD-L1 value and PD-L1 expression in tu
BackgroundExpression of programmed-death ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) is typically evaluated through invasive biopsies; however, recent advances in the identification of circ
Background: Combination therapy with immune checkpoint inhibitors (ICIs) has been widely used for clinical treatment in recent years, which has a better survival benefit. However, not all patients can
Supplementary Table 1. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisBayesian ranking results of network meta-analysis. PlaCT= platinum-bas
